Medifast

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm’s product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medifast reports Q4 revenue decline, focuses on cost management

Medifast's Q4 2022 performance saw revenue decline but strong cost management and cash generation.
Challenges include revenue outlook for Q1 2023 and competitive landscape in weight loss and coaching markets.
Opportunities lie in capital allocation strategies, maintaining shareholder value, and adapting to market trends.
Overall, Medifast remains focused on long-term growth, financial stability, and delivering on its mission.

Medifast surpasses Q1 expectations, eyes growth amid operational tweaks

Medifast's Q1 2023 performance exceeded expectations, with a focus on revenue growth and cost control measures.
Despite challenges like decreased active coaches, the company is well-positioned with a strong financial standing and growth initiatives.
Opportunities in customer acquisition, cost-saving efforts, market expansion, and innovative solutions pave the way for future success.
Guidance for Q2 2023 reflects a strategic approach to balancing growth and profitability amidst market dynamics and operational changes.

Medifast reports Q2 revenue decline, eyes sustainable growth strategies

Medifast navigated challenges in Q2 2023 with improved operating margin and strategic market exits.
The company's focus on new growth initiatives and cost-saving measures reflects adaptability to market dynamics.
While facing revenue declines and competitive pressures, Medifast aims for sustainable growth with clear targets.
Exploration of medically supported weight loss solutions and new product lines offer avenues for future expansion.

Medifast reports resilient Q3 performance, eyes growth through diversification

Medifast's Q3 performance reflects resilience amid revenue decline, with a focus on operational efficiency and financial strength. While facing challenges in revenue and expense management, the company remains agile and proactive in exploring growth opportunities through market expansion and social responsibility initiatives.

Medifast transitions to health and wellness focus amidst revenue challenges

Medifast is navigating challenges in customer acquisition and macro factors while focusing on becoming a diversified health and wellness company.
The company's strategic collaboration with Life MD and new product offerings position it for growth.
While Q4 2023 saw a revenue decrease, Medifast's improved gross profit margin and cost-saving initiatives demonstrate operational efficiency.
Investors should monitor the impact of increased marketing spending on operating margin and EPS in the coming years.

Medifast faces revenue decline due to weight loss medication trends

Medifast's Q1 2024 performance reflects challenges in revenue and income, driven by difficulties in customer acquisition amidst weight loss medication trends.
Despite the decline, the company demonstrated operational efficiency with improved gross profit margins and cost management.
Investments in marketing and collaborations present opportunities for future growth and market expansion, signaling a strategic focus on long-term success.
Navigating market challenges while capitalizing on opportunities will be crucial for Medifast's resilience and competitiveness in the weight loss industry.

Medifast reports Q2 losses, focuses on growth strategies and cost management

Medifast's Q2 2024 performance reflects a challenging period marked by revenue and profit declines, offset by margin improvements and cost reductions.
The company's strategic initiatives aim to drive long-term growth and enhance operational efficiency amidst macroeconomic headwinds and lower coach productivity.
While facing financial setbacks, Medifast's focus on targeted advertising, product diversification, and cost management signifies a proactive stance towards future recovery and growth.

Medifast adapts to industry changes with tailored programs and innovations

Medifast's Q3 2024 performance reflected revenue and net income declines, highlighting challenges in the weight loss industry.
Despite these challenges, the company's strategic focus on tailored programs, strong financial position, and new product launches indicate a proactive approach to addressing market dynamics.
Opportunities in clinical studies, new product launches, and financial strength position Medifast for potential growth and market expansion in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medifast, Inc. is a health and wellness company. engages in the habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple yet comprehensive approach to address obesity and support a healthy lifestyle. The company was founded by William Vitale in 1980 and is headquartered in Baltimore, MD.

Autohome

Chemed

Dick's Sporting Goods

Ensign Group

Evercore

Gentex

Garmin

Houlihan Lokey

Johnson Outdoors

Kforce

Lithia Motors

Logitech

PulteGroup

The American Association of Individual Investors (AAII) publishes monthly tips for members on-line. Their November Journal featured these thirty Buffett-worthy candidates by one of Buffett's closest followers, Robert Hagstrom.

Tracking Warren Buffett's Future Dividend Picks: 21 From AAII's Hagstrom Screen

Griffon

MKS Instruments

Radiant Logistics

As of Nov. 18, the following stocks look underestimated by the market, as their price-earnings ratios without non-recurring items (NRI) trade below 20 while their price-earnings to growth (PEG) ratios trade near or below 1.

4 Stocks That Look Like Potential Bargains

Is Medifast (MED) a great pick from the value investor's perspective right now? Read on to know more.

Should Value Investors Pick Medifast (MED) Stock Now?

Alibaba

British American Tobacco

The red hot market continues, with stocks rising for eight straight days, and five straight weeks (this could be the sixth). The S&P 500 is now 30% overvalued.

3 Blue-Chips That Could Triple In The Next 5 Years

Herbalife

Nu Skin Enterprises

Primerica

The FTC sent warning letters to 1,100 companies, 700 of them MLM companies. Milton Friedman recognized that competitive markets do not benefit from deception and fraud.

Can The Federal Trade Commission Drain A Swamp?

Medifast's (MED) third-quarter 2021 results reflect stellar earnings and revenues, courtesy of continued strength in OPTAVIA. Management raises earnings per share and revenue guidance for 2021.

Medifast (MED) Raises View on Q3 Earnings & Revenue Beat

Medifast, Inc. (MED) CEO Dan Chard on Q3 2021 Results - Earnings Call Transcript

Medifast (MED) delivered earnings and revenue surprises of 21.92% and 1.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Medifast (MED) Q3 Earnings and Revenues Surpass Estimates

BALTIMORE, Nov. 4, 2021 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities,  OPTAVIA® , today reported results for the third quarter ended September 30, 2021. Third Quarter 2021 Highlights Compared to the Prior-Year Period Revenue increased 52.3% to $413.4 million 44.9% growth in active earning OPTAVIA Coaches to a record level of 61,000 Revenue per active earning OPTAVIA Coach increased 7.0% to new high of $6,773 Net income increased 21.9% to $42.0 million Earnings per diluted share ("EPS") of $3.56, an increase of 22.3% "We saw continued strong momentum during the third quarter, reflecting our ongoing success in offering a differentiated and personalized health and wellness program to a growing community of clients across the United States and Asia Pacific.

Medifast, Inc. Announces Third Quarter 2021 Financial Results

Medifast's (MED) third-quarter results are likely to reflect gains from the OPTAVIA lifestyle solution and coaching support system, though high costs are a concern.

Factors to Consider as Medifast (MED) Gears Up for Q3 Earnings

Medifast (MED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medifast (MED) Earnings Expected to Grow: Should You Buy?

BALTIMORE, Oct. 21, 2021 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, will announce financial results for the third quarter ended September 30, 2021 on Thursday, November 4, 2021, after market close. The Company will host a conference call to discuss the results with additional comments and details.

Medifast, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2021

Ameriprise Financial

Anthem

D.R. Horton

JPMorgan Chase & Co

Mastercard

Marsh & McLennan

Microsoft

Raymond James

SPDR S&P 500 ETF Trust

T. Rowe Price Group

Tata Motors

Visa

This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration. To rank stocks, I use DVK Quality Snapshots to obtain quality scores, sort them in descending order, and break ties with additional metrics.

10 Dividend Growth Stocks For October 2021

Medifast (MED) has long been gaining on the strength of its OPTAVIA lifestyle solution and coaching support system, while rising SG&A costs are a worry.

Medifast's (MED) OPTAVIA System a Key Driver, SG&A Costs High

BALTIMORE, Oct. 11, 2021 /PRNewswire/ -- Medifast (NYSE: MED), the global company behind one the fastest-growing health and wellness communities, OPTAVIA ®, hosted its third annual Healthy Habits For All® Week Monday, Sept. 20 through Sunday, Sept.

Medifast and its OPTAVIA Community Promote Healthy Habits around the World with Third Annual Philanthropic Event

MED is one of the most impressive dividend growers in the market. Since 2017 the company grew its top and bottom line by double-digit growth and is expected to continue to do so in the next years.

Medifast: A 5-Year Dividend CAGR Of 48%, But No Moat

Amarin Corporation Plc

When looking for top stocks, instead of traditional valuation measures, look at stocks trading well below their upside potential. The post 3 Top Stocks With Upsides Over 50%, According to Wall Street Analysts appeared first on InvestorPlace.

3 Top Stocks With Upsides Over 50%, According to Wall Street Analysts

Medifast has great financials and a deep moat around its business. The company grew its quarterly dividend by almost 500% since 2016 and currently has a dividend yield of 3%.

Medifast: Perfect For Dividend-Growth Investors

Campbell Soup

Ethan Allen Interiors

Hamilton Beach Brands Hld

H&R Block

Mondelez

Whirlpool

This collection of consumer stocks combines growth potential with a solid dividend track record. Here's why each should be on your radar.

7 Consumer Stocks That Are Also Serving Up Delicious Dividends

Medifast (MED) has been benefiting from its OPTAVIA lifestyle solution and coaching support system as well as focus on capacity expansion and technological advancements.

Medifast (MED) Worth Relishing on OPTAVIA Strength, Growth Plans

BALTIMORE, Sept. 15, 2021 /PRNewswire/ -- Medifast (NYSE: MED), the global company behind one the fastest-growing health and wellness communities, OPTAVIA®, released findings from back-to-back surveys designed to explore whether people seek support in achieving their health and wellness goals.

81% of U.S. Adults Value Support from Someone with Similar Experiences when Creating Healthy Habits

Is (MED) Outperforming Other Consumer Staples Stocks This Year?

Has MEDIFAST INC (MED) Outpaced Other Consumer Staples Stocks This Year?

Medifast (MED) reported earnings 30 days ago. What's next for the stock?

Why Is Medifast (MED) Down 10.8% Since Last Earnings Report?

Delta Apparel

Service Corp

Delta Apparel (DLA), MEDIFAST (MED) & Service Corporation International (SCI) are at present the three top efficient stocks that need to be added to your portfolio.

3 of the Best Efficient Stocks to Boost Your Portfolio

Medifast (MED) has been benefiting from the strength of its OPTAVIA lifestyle solution and coaching support system as well as strategic growth endeavors like technological advancements.

News for Medifast Stock (MED)